Treatment Information

Back

Melanoma treatment details. Chemotherapy, Immunotherapy.

Istituto Nazionale per lo Studio e la Curra dei Tumori, Milan, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Milan
Treatments:Chemotherapy, ImmunotherapyHospital:Istituto Nazionale per lo Studio e la Curra dei Tumori
Drugs:Journal:Link
Date:Feb 2006

Description:

Patients: This phase III study involved 151 patients with metastatic melanoma. Patients were divided into two groups: Group A had 75 patients and Group B had 76 patients. The median age for Group A was 51.5 and the median age for Group B was 46.5.

Treatment: For both groups, patients received chemotherapy (cisplatin, vindesine, decarbazine). In addition, patients in Group B received immunotherapy (interleukin-2 and interferon-alpha2b).

Toxicity: For both groups toxicities included: grade 3/4 fever, anemia, asthenia/fatigue, nausea and neutropenia.

Results: For Group A (chemotherapy only) the overall median survival was 12 months. For Group B (chemotherapy plus immunotherapy) the overall median survival was 11 months. The authors concluded that the addition of immunotherapy is not better than chemotherapy alone.

Correspondence: Dr. E. Bajetta




Back